Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18109834 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP2D6HRH1KMT2APKM | |
| SCHEMBL19616859 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP2D6HRH1KMT2APKM | |
| SCHEMBL15657167 | 0.89 | — | — | |
| SCHEMBL16621306 | 0.89 | — | — | |
| SCHEMBL13655082 | 0.89 | — | — | |
| SCHEMBL14968360 | 0.88 | HRH3 (0.39) | SMN1; SMN2HRH3MAPK1BCHE | |
| Hydrochloric Acid SCHEMBL25366707 | 0.87 | SLC18A3 (0.40) | ALDH1A1CYP2D6HRH1KMT2APKM | |
| Hydrochloric Acid SCHEMBL25367874 | 0.87 | SLC18A3 (0.40) | ALDH1A1CYP2D6HRH1KMT2APKM | |
| Hydrochloric Acid SCHEMBL25366712 | 0.87 | SLC18A3 (0.40) | ALDH1A1CYP2D6HRH1KMT2APKM | |
| SCHEMBL735658 | 0.79 | HRH3 (0.38) | HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3844151-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-109843856-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20190270743-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-09-05 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| EP-3458445-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 3370/4885CYP2D6 3803/4885HRH1 1684/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | ALDH1A1 3370/4885CYP2D6 3803/4885HRH1 1684/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 3370/4885CYP2D6 3803/4885HRH1 1684/4885 |
| US-20190270743-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 3370/4885CYP2D6 3803/4885HRH1 1684/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 3370/4885CYP2D6 3803/4885HRH1 1684/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 3370/4885CYP2D6 3803/4885HRH1 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.